Company news
China NT Pharma Group Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 3, 2026
Quarterly updates on the implementation of action plans to resolve the disclaimer of opinion
October 30, 2026
Voluntary announcement in relation to the application for revocation of the first arbitral award and litigation in respect of the equity interest in beijing kangchen biological technology co., limited
October 30, 2026
Supplemental announcement supplemental information in relation to the annual report for the year ended 31 December 2025
October 23, 2026
Notification Letter and Request Form to Non-Registered Holder
October 20, 2026
Notification Letter and Reply Form to Registered Shareholder
October 20, 2026
Form of proxy for use at extraordinary general meeting
October 20, 2026
Notice of extraordinary general meeting
October 20, 2026
Appointment of auditor and notice of extraordinary general meeting
October 20, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 6, 2026
Notification Letter and Request Form to Non-Registered Holder
September 29, 2026
Notification Letter and Reply Form to Registered Shareholder
September 29, 2026
2026 Interim Report
September 29, 2026
Voluntary announcement in relation to the application for compulsory enforcement by a wholly-owned subsidiary in respect of the shareholders' right to information of beijing kangchen biological technology co., limited
September 25, 2026
Inside information announcement arbitration award
September 25, 2026
Appointment of auditor
September 14, 2026
Connected transaction in relation to loan capitalisation involving subscription of shares under Specific mandate
June 17, 2026
Supplemental announcement retirement of auditor
June 11, 2026
China NT Pharma Group: Proposed granting of general mandates to issue shares and repurchase shares, proposed re-election of retiring directors and notice of annual general meeting
April 30, 2021
Profit warning supplemental announcement
August 6, 2020
Voluntary announcement shusi approved in consistency evaluation
February 20, 2020
Appointment and resignation of independent non-executive director and change of member of board committees
December 31, 2019
Resignation of executive and non-executive directors and change of chief financial officer
November 29, 2019
China NT Pharma Group: Monthly progress update in relation to (1) major and connected transaction in respect of the acquisition and subscription of shares and convertible bonds of Hong Kong wd pharmaceutical co., Limited (2) issue of consideration shares under Specific Mandate and (3) application for Whitewash Waiver
October 29, 2019
Extension of conditions precedent long stop date and further delay in despatch of circular in relation to (1) major and connected transaction in respect of the acquisition and subscription of shares and convertible bonds of Hong Kong wd pharmaceutical co., Limited (2) issue of consideration shares under Specific Mandate and (3) application for Whitewash Waiver
September 30, 2019
Further delay in despatch of circular in relation to (1) major and connected transaction in respect of the acquisition and subscription of shares and convertible bonds of Hong Kong wd pharmaceutical co., Limited (2) issue of consideration shares under Specific Mandate and (3) application for Whitewash Waiver
September 6, 2019
China NT Pharma Group: Proposed granting of general mandates to issue shares and to repurchase shares and proposed re-election of retiring directors and notice of annual general meeting
April 27, 2017
Supplemental Agreement in Relation to Proposed Issuance of Convertible Preference Shares
April 24, 2017
(1) Proposed Issue of Convertible Preference Shares (2) Proposed Grant of Specific Mandate t…
April 20, 2017
Annual Results Announcement for the Year ended 31 December 2016
March 22, 2017
Voluntary announcement nt biopharma obtained new gmp certification from cfda production and sales of national class 1.1 new drug “xi di ke” will officially commence
March 10, 2017
Announcement of Approval of Xi Di Ke (Uroacitides Injection), National Class 1.1 New Drug to…
January 4, 2017
Voluntary Announcement - NT Pharma Successfully Makes Payment of Acquisition on Miacalcic I…
December 19, 2016
Voluntary announcement unusual price movement and intention to conduct on-market share rep…
December 15, 2016